The Cost-Effectiveness Of Canagliflozin Verse Liraglutide In Patients With Type 2 Diabetes (T2dm) Failing To Achieve Glycaemic Control On Metformin Monotherapy In Ireland.
نویسندگان
چکیده
1. American Diabetes Association. Diabetes Care. 2014;37(Suppl 1):S14-S80. 2. Department of Health and Children. Changing Cardiovascular Health: National Cardiovascular Health Policy, 2010-2019. Dublin, Ireland: Department of Health and Children; 2010. http://www.dohc.ie/publications/pdf/changing_cardiovascular_ health.pdf. Accessed 3 Oct 2014. 3. Canavan R. Presented at: National Association of General Practitioners Annual General Meeting; 23 November 2013; Dublin, Ireland. 4. Smith D. Presented at: 6th All-Ireland Conference of the Primary Care Diabetes Society; 13 April 2013; Athlone, Ireland. 5. Inzucchi SE, et al. Diabetologia. 2012;55(6):1577-1596. 6. Rosenstock J, et al. Diabetes Care. 2012;35(6):1232-1238. 7. Stenlöf K, et al. Diabetes Obes Metab. 2013;15(4):372-382. 8. Lavalle-González FJ, et al. Diabetologia. 2013;56(12):2582-2592. 9. Wilding JP, et al. Int J Clin Pract. 2013;67(12):1267-1282. 10. Forst T, et al. Diabetes Obes Metab. 2014;16(5):467-477. 11. Stenlöf K, et al. Curr Med Res Opin. 2014;30(2):163-175. 12. Yale JF, et al. Diabetes Obes Metab. 2013;15(5):463-473. 13. Yale JF, et al. Diabetes Obes Metab. 2014;16(10):1016-1027. 14. Cefalu WT, et al. Lancet. 2013;382(9896):941-950. 15. Schernthaner G, et al. Diabetes Care. 2013;36(9):2508-2515. 16. Leiter LA, et al. Diabetes Care. 2014. doi:10.2337/dc13-2762. 17. Bode B, et al. Hosp Pract. 2013;41(2):72-84. 18. Devineni D, et al. Diabetes Obes Metab. 2012;14(6):539-545. 19. Sha S, et al. PLoS One. 2014;9(8):e105638. 20. Devineni D, et al. J Clin Pharmacol. 2013;53(6):601-610. 21. O’Leary A, et al. Value Health. 2012;15(7):A506. 22. Willis M, et al. J Med Econ. 2013;16(8):1007-1021. 23. INVOKANATM (canagliflozin) tablets, for oral use [summary of product characteristics]. Beerse, Belgium: Janssen-Cilag International NV; 2013. 24. Pacou M, et al. Value Health. 2013;16(7):A609. 25. Janssen Research & Development. Integrated summary of efficacy. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. 2012. 26. Kahn SE, et al. N Engl J Med. 2006;355(23):2427-2443. 27. Hayes AJ, et al. Diabetologia. 2013;56(9):1925-1933. 28. Bagust A, Beale S. Health Econ. 2005;14(3):217-230. 29. Currie CJ, et al. Curr Med Res Opin. 2006;22(8):1523-1534. 30. Shingler SL, et al. Value Health. 2013;16(7):A445. 31. Balasanthiran A, et al. Practical Diabetes. 2012;29(4):144-146.
منابع مشابه
Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico
Objective: To assess the cost-effectiveness of canagliflozin versus sitagliptin for the treatment of type 2 diabetes mellitus (T2DM) as an add-on to metformin in Mexico. Methods: A validated model (Economic and Health Outcomes [ECHO]-T2DM) was used to estimate the cost-effectiveness of canagliflozin 300 or 100 mg versus sitagliptin 100 mg in patients with T2DM inadequately controlled on metform...
متن کاملEvaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
BACKGROUND Effective glycemic control can reduce the risk of serious micro- and macrovascular complications in type 2 diabetes. However, many patients fail to reach glycemic targets due partly to low efficacy and adverse effects of treatment such as hypoglycemia or weight gain. OBJECTIVE To evaluate the short-term cost-effectiveness of liraglutide versus sitagliptin, in terms of cost per pati...
متن کاملFixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview
Metformin is recommended as a first-line therapy for patients with type 2 diabetes mellitus (T2DM). However, many patients do not achieve glycemic goals with metformin monotherapy and require subsequent combination therapy with other antihyperglycemic agents (AHAs). For newly diagnosed patients with high blood glucose, initial combination therapy may be required to achieve glycemic control. The...
متن کاملCanagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes
Metformin is typically the first pharmacologic treatment recommended for type 2 diabetes mellitus (T2DM), but many patients do not achieve glycemic control with metformin alone and eventually require combination therapy with other agents. Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, was assessed in a comprehensive Phase 3 clinical development program consisting of ~10,000...
متن کاملIncretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
INTRODUCTION Treatment with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, which target the incretin axis, has the potential to improve glycemic control in type 2 diabetes patients without the weight gain associated with traditional therapies. To evaluate the relative cost-effectiveness of incretin therapies, the present study aimed to compare the long-term cli...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 17 7 شماره
صفحات -
تاریخ انتشار 2014